Genentech: FDA Approves Tecentriq Plus Chemotherapy for Some Non-Small Cell Lung Cancer
December 03 2019 - 7:21PM
Dow Jones News
By Stephen Nakrosis
Genentech said Tuesday the Food and Drug Administration approved
its Tecentriq plus chemotherapy to treat certain lung cancers.
The company said the approval was for the initial treatment of
certain adults with metastatic non-squamous non-small cell lung
cancer.
Genentech said the approval was based on results from a Phase
III study that showed Tecentriq, or atezolizumab, "in combination
with chemotherapy helped people live significantly longer compared
to chemotherapy alone."
Genentech is a member of the Roche Group.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 03, 2019 19:06 ET (00:06 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2024 to May 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From May 2023 to May 2024